We’re not testing drugs but Oxfam should randomize more

Franziska Mager Inequality, Research

Oxfam should expand its toolkit for understanding support for the problems we care about among the UK public, argues Franziska Mager. You might think that when it comes to research, Oxfam’s ways of working have near nothing in common with a pharmaceutical company. I argue that the one thing which our public facing teams should adopt from these companies is …